371 related articles for article (PubMed ID: 25722110)
21. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
Pan Y; Li K; Tao X; Zhao Y; Chen Q; Li N; Liu J; Go VLW; Guo J; Gao G; Xiao GG
Pancreas; 2021 Oct; 50(9):1260-1266. PubMed ID: 34860809
[TBL] [Abstract][Full Text] [Related]
24. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upregulating TWF1.
Hua YQ; Zhu YD; Xie GQ; Zhang K; Sheng J; Zhu ZF; Ning ZY; Chen H; Chen Z; Meng ZQ; Liu LM
Aging (Albany NY); 2019 Nov; 11(20):8860-8878. PubMed ID: 31619579
[TBL] [Abstract][Full Text] [Related]
25. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
[TBL] [Abstract][Full Text] [Related]
26. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
[TBL] [Abstract][Full Text] [Related]
27. An Integrated Data Analysis of mRNA, miRNA and Signaling Pathways in Pancreatic Cancer.
Sohrabi E; Rezaie E; Heiat M; Sefidi-Heris Y
Biochem Genet; 2021 Oct; 59(5):1326-1358. PubMed ID: 33813720
[TBL] [Abstract][Full Text] [Related]
28. Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling.
Zhou M; Ye Z; Gu Y; Tian B; Wu B; Li J
Int J Clin Exp Pathol; 2015; 8(1):38-52. PubMed ID: 25755691
[TBL] [Abstract][Full Text] [Related]
29. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.
Okamoto K; Miyoshi K; Murawaki Y
PLoS One; 2013; 8(10):e77623. PubMed ID: 24147037
[TBL] [Abstract][Full Text] [Related]
30. PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer.
Liu YF; Luo D; Li X; Li ZQ; Yu X; Zhu HW
Pancreas; 2021 Feb; 50(2):227-234. PubMed ID: 33565800
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I
Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
[TBL] [Abstract][Full Text] [Related]
33. Construction of microRNA-messenger networks for human osteosarcoma.
Ma G; Zhang C; Luo W; Zhao JL; Wang X; Qian Y
J Cell Physiol; 2019 Aug; 234(8):14145-14153. PubMed ID: 30666640
[TBL] [Abstract][Full Text] [Related]
34. Identification of miRNA-mRNA crosstalk in pancreatic cancer by integrating transcriptome analysis.
Yang J; Zeng Y
Eur Rev Med Pharmacol Sci; 2015; 19(5):825-34. PubMed ID: 25807437
[TBL] [Abstract][Full Text] [Related]
35. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
Ma G; Sun Y; Fu S
Int J Clin Exp Pathol; 2015; 8(10):13284-8. PubMed ID: 26722531
[TBL] [Abstract][Full Text] [Related]
37. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes.
Zhou C; Yi C; Yi Y; Qin W; Yan Y; Dong X; Zhang X; Huang Y; Zhang R; Wei J; Ali DW; Michalak M; Chen XZ; Tang J
Mol Cancer; 2020 Jul; 19(1):118. PubMed ID: 32727463
[TBL] [Abstract][Full Text] [Related]
38. miR-33a suppresses the nuclear translocation of β-catenin to enhance gemcitabine sensitivity in human pancreatic cancer cells.
Liang C; Wang Z; Li YY; Yu BH; Zhang F; Li HY
Tumour Biol; 2015 Dec; 36(12):9395-403. PubMed ID: 26113407
[TBL] [Abstract][Full Text] [Related]
39. Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.
Tu MJ; Ho PY; Zhang QY; Jian C; Qiu JX; Kim EJ; Bold RJ; Gonzalez FJ; Bi H; Yu AM
Cancer Lett; 2019 Feb; 442():82-90. PubMed ID: 30389433
[TBL] [Abstract][Full Text] [Related]
40. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Ma L; Fan Z; Du G; Wang H
Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]